Galmed Pharmaceuticals (GLMD) Earnings Analysis

Galmed Pharmaceuticals (GLMD) next reports earnings on 2026-07-30, consensus EPS -0.39 USD. Last quarter (2026-07-08) it beat with EPS -0.29 USD vs -0.38 USD est (+23.7%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -0.25.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GLMD next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.39 USD
Revenue estimaten/a

GLMD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-07-08-0.29 USD-0.38 USD+23.7%Beat
2025-11-26-0.33 USD-0.54 USD+38.9%Beat
2025-08-280.63 USD-0.83 USD+175.9%Beat
2025-05-22-0.62 USD-0.89 USD+30.3%Beat
2025-04-02-1.94 USD-0.89 USD-118%Miss
2024-11-14-2.31 USDn/an/an/a
2024-08-282.16 USDn/an/an/a

Beat rate: 4/5 (80%) over reported quarters with consensus data.

GLMD valuation and analyst view

Trailing P/E-0.25
Trailing EPS-1.68628 USD
Price / book0.24
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (10 buy / 6 hold / 0 sell)

Related research pages

Frequently asked questions

When is Galmed Pharmaceuticals (GLMD)'s next earnings date?

Galmed Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.39 USD.

Did GLMD beat earnings last quarter?

In its 2026-07-08 report, GLMD posted EPS of -0.29 USD versus a -0.38 USD estimate — a beat of 23.7%.

What is GLMD's earnings track record?

Over the last 5 reported quarters with consensus data, GLMD beat estimates 4 times (80%).

What is GLMD's current P/E ratio and EPS?

GLMD trades at a trailing P/E of -0.25 on trailing EPS of -1.6862766813650119 USD.

What do analysts rate GLMD?

Analyst consensus is "Buy" across 16 ratings (0 strong buy, 10 buy, 6 hold, 0 sell, 0 strong sell).